The utility of complete blood parameter indices to predict stillbirths
Journal of Maternal-Fetal and Neonatal Medicine, cilt.36, sa.1, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 36 Sayı: 1
- Basım Tarihi: 2023
- Doi Numarası: 10.1080/14767058.2023.2183747
- Dergi Adı: Journal of Maternal-Fetal and Neonatal Medicine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, MEDLINE
- Anahtar Kelimeler: Stillbirth, pregnancy, inflammation, complete blood parameter indices
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: In this study, we aimed to investigate the relationship between unexplained stillbirth (SB) cases and the complete blood parameter indices and we compared them with uncomplicated healthy cases. Methods: Patients diagnosed with unexplained SB cases in a tertiary center between 2019-2022 were included in this retrospective case-control study. The gestational age threshold for SBs was accepted as births after the 20th week of pregnancy. Consecutive patients with no adverse obstetric outcomes were accepted as the control group. Patients’ complete blood parameter results at the time of the first admission to the hospital until 14 weeks were labeled as “1’’ and at the time of delivery were labeled as “2’’ and recorded. As inflammatory parameters, neutrophile-lymphocyte ratio, derivated neutrophile-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio (LMR), and hemoglobin-lymphocyte ratio (HLR) were calculated from complete blood results and recorded. Results: There were statistically significant differences between the groups’ LMR1 (p =.040). Additionally, whereas HLR1 of the study group was 0.693 (0.38–2.72), it was 0.645 (0.15–1.82) in the control group (p =.026). However, the HLR2 of the study group was significantly lower than the control group (p =.021). Conclusion: Necessary precautions such as fetal biophysical profile examination can be taken more frequently in the antenatal follow-up in patients considered to be at high risk of SB by using HLR. It is a novel marker that can be easily accessible and calculated from the complete blood parameters.